Search results for Aop Orphan Pharmaceuticals

<![CDATA[Angelini Pharma Enters $ 4.1 Billion Agreement to Acquire Catalyst Pharmaceuticals ]]>

Rare Disease Business As Usual

Rare Disease Business As Usual Anonymous (not verified) Sun, 05/10/2026 - 08:23 field_thread_url https://cafepharma.com/boards/threads/rare-disease-busines...

<![CDATA[First Patient Dosed with Azenosertib in Aspenova Phase III Trial for Treatment of Ovarian Cancer]]>

Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalen...

TORONTO, May 1, 2026 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), Canada's largest Canadian‑based global health company, today announced that Health Canada has approved...

Tolmar Pharmaceuticals

Tolmar Pharmaceuticals Anonymous (not verified) Sat, 04/11/2026 - 05:03 field_thread_url https://cafepharma.com/boards/threads/tolmar-pharmaceuticals.56651...

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>

<![CDATA[Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement]...

Australia’s Immutep rallies over 100% on FDA orphan drug designation

<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-P...

FDA hold puts Aardvark Prader-Willi drug in limbo

The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.

Option Care (OPCH) Climbs 5.9% on US Healthcare Developments

Amplia targets ovarian cancer in new clinical protein inhibitor trial

Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.

Recordati Rare Disease

Recordati Rare Disease Anonymous (not verified) Sat, 04/18/2026 - 08:08 field_thread_url https://cafepharma.com/boards/threads/recordati-rare-disease.68363...

Orbicular gets USFDA’s tentative nod for generic Semaglutide Injection in partnership with Apotex

The product will be marketed and commercialised in the United States by Apotex Corp., the ANDA applicant

<![CDATA[FDA Places Full Clinical Hold on Aardvark Therapeutics’ ARD-101]]>

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

<![CDATA[Pharma M&A Roundup: IMG Pharma Acquires Matsumoto Pharmaceutical, Sun Pharma Acquires Organon ]]>

Rare disease turned into Primary Care sales force

Rare disease turned into Primary Care sales force Anonymous (not verified) Tue, 05/12/2026 - 11:23 field_thread_url https://cafepharma.com/boards/threads/r...

Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development

Aptose Biosciences has scrapped a deal for a blood cancer drug candidate as part of its pending takeover by Hanmi Pharmaceutical.

Indian drugmakers look beyond generics as Sun Pharma buys Organon

Sun Pharma Aims for Top 3 in Women’s Health with $11.75B Organon Purchase

Sun Pharma and Organon said the combined company would rank among the top three in global women’s health, become the world’s seventh‑largest biosimilar player, and operate in 150 c...

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cispla...

PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to